Cytokine Release Syndrome and the IL-6 Axis
Tocilizumab reverses cytokine release syndrome within hours, and it does not touch the cell that started it. That is the whole shape of this map. The trigger is a T cell — engaged by a CAR, a bispecific or an infection — but the syndrome is built by monocytes and macrophages downstream, and it runs through one cytokine hard enough that blocking a single receptor collapses it. IL-6 is that cytokine, and it signals two different ways: classic, through membrane IL-6R on a handful of cell types, and trans, through soluble IL-6R on any cell that carries gp130 — which is all of them. Understanding which arm you are blocking is the difference between a targeted intervention and a blunt one. Click any protein for the matching Assay Genie ELISA kit or In Vivo antibody.
The T cell pulls the trigger; the monocyte builds the storm. This is the single most useful thing to know about CRS, and it is why tocilizumab works without abolishing the therapy's efficacy. An engaged T cell releases IFN-γ, IL-2 and GM-CSF within hours. Those act on monocytes and macrophages, which produce the bulk of the IL-6, IL-1β and TNF that cause the fever, hypotension and capillary leak. Serum IL-6 in severe CRS is overwhelmingly myeloid in origin, not T-cell. Deplete monocytes in a mouse model and the CAR-T cells still kill the tumour while the syndrome largely disappears — which is the experiment that settled the question.
Classic versus trans-signalling is the reason one antibody outperforms the other. Membrane IL-6R is restricted to hepatocytes, neutrophils, monocytes and some lymphocytes. ADAM17 sheds it, and the resulting soluble IL-6R lets IL-6 signal through gp130 on any cell in the body — endothelium included. That is trans-signalling, and it is the arm that drives the vascular pathology. Tocilizumab binds IL-6R and blocks both arms; siltuximab binds the ligand. Blocking the receptor is generally the more complete intervention, which is the same lesson the chemokine and VEGF maps teach from different directions. Downstream is short: JAK1 to STAT3, restrained by SOCS3 — which is why JAK inhibitors are being trialled here at all.
The acute-phase response is the readout, and it is slower than the patient. STAT3 in the hepatocyte drives CRP, serum amyloid A, fibrinogen, hepcidin and ferritin, and suppresses albumin. CRP is the standard bedside proxy for IL-6 but it lags by roughly a day, so a falling IL-6 with a still-rising CRP is expected rather than paradoxical. Hepcidin explains the functional iron deficiency; ferritin above roughly 10,000 µg/L, together with soluble CD25, should prompt the question of whether this is CRS or secondary HLH, because the management diverges at that point.
Then the endothelium fails. Angiopoietin-2, von Willebrand factor, ICAM-1 and VCAM-1 mark the transition from a febrile patient to a hypotensive one, and a high pre-treatment ANG-2:ANG-1 ratio identifies patients who will get severe CRS before they get it. The In Vivo tie-in, stated plainly: 10 of 37 nodes carry a functional-grade antibody — but IL-6 and IL-6R are not among them. The central node of this map is measurable, not blockable, in the In Vivo range. What is blockable is the layer either side of it: the trigger (CD3, CD19, CD20, IL-2, IFN-γ) and the amplifier (IL-1β, IL-1R1 — anakinra's target and the second-line CRS drug — TNF, GM-CSF, ICAM-1). And unusually, the drugs themselves are measurable: tocilizumab, siltuximab and canakinumab all have free-drug ELISA kits, so exposure can be confirmed rather than assumed. For research use only; not for use in diagnostic or therapeutic procedures.
Every protein node links to a product — ELISA kit, In Vivo antibody or research antibody.